Explore comprehensive CDMO and CRO services offered by Aurisco Pharmaceutical Co Ltd, supporting end-to-end Manufacturing. Aurisco Pharmaceutical Co Ltd enables faster, compliant, and scalable pharma innovation tailored to your needs.
Country: China
Description: Aurisco Pharmaceutical Co., Ltd., founded in 1998, is a Shanghai-based public company that develops and manufactures complex Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company has a focus on complex synthesis, synthetic biology, and oligonucleotide synthesis, and serves global markets through its manufacturing sites and sales offices in various countries. Listed on the Shanghai Stock Exchange since 2020 (stock code 605116), Aurisco is a partner to major pharmaceutical companies and has a strong emphasis on quality, innovation, and ESG principles.
